Clinical trial

TWEAK, a New Biomarker for Predicting Inflammatory Relapses in Multiple Sclerosis

NCT03974997

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2023-06-16

PhaseNA

Study timeline

Study start (actual)2023-06-16Date precision: day

Registry last updated2026-09-23

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Multiple Sclerosisverified · MONDO: multiple sclerosis

Interventions

Determination of the circulating serum concentration of cytoquine TWEAKDIAGNOSTIC_TEST

Sponsors & collaborators

Assistance Publique Hopitaux De Marseillelead sponsor

Mapped research locations

MarseilleFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03974997 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.